Théa Signs License Option Agreement for Elsalys’ Retinal Candidate

March 2, 2018: By Joan McKenna

France-based Théa Laboratories has signed a license option agreement for Elsalys Biotech’s ELB011 program in ophthalmology, Elsalys announced Feb. 22.

Elsalys describes ELB011 as a first-in-class antibody that demonstrates an anti-angiogenic effect on the formation of new blood vessels which cause certain retinal diseases, including age-related macular degeneration (AMD).

Target diseases for ELB011 are wet AMD, proliferative diabetic retinopathy, and diabetic macular edema.

Under the agreement, Théa will pay Elsalys an up-front payment of an undisclosed amount, plus milestone payments and royalties on sales. Théa said its exercise of the option could take place by the end of 2018.

Elsalys, a new French company focused on immuno-oncology, will remain in charge of the initial steps of preclinical development and the production of batches for toxicology studies and clinical trials. Théa will be responsible for full clinical development and commercialization in ophthalmology.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

STAAR’s 2017 Net Sales Total $90.6 Million

US FDA Warns Consumers Not to Use Products from Cantrell Drug Company

IDx’ AI-Based Diagnostics System Meets Endpoints in Pivotal Trial for DR

Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

Carl Zeiss Meditec Reports $359.7 Million in Revenues for First Quarter of FY2018, a 5.3 Percent Increase

Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

Coming soon

2018 IOL Report: A Global Market Analysis for 2017 to 2023